Tue 8/4/2020 11:11 ET
DJIA26745.4880.240.30%TELCO170.932.461.44%GOLD1991.7118.720.94%Shanghai3371.693.710.11%
S&P 5003299.254.620.14%BANKS335.021.570.47%OIL41.310.300.73%BITCOIN11211.0833.630.30%
NASDAQ10906.603.270.03%PHARM621.880.620.10%US/EU1.180.000.08%Futures3293.254.610.14%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Exelixis - EXEL)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add EXEL
  
From: ch90 (Rep: 29)Date: 07/20/2015 07:43
Forum: Wall Street Pit - Msg #2557054 - List EXEL msgs Thread #673764411 (Rec: 0)
+60% PM

Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma

http://finance.yahoo.com/news/exelixis-announces-positive-top-line-110000554.html

NOTE: This message has been revised 1 time. Read original version of this message.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser ch90: Reward | Watch | IgnoreEXEL: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add EXEL
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 2020- TheLion.com, Inc.